Formation and Distribution of NNK Metabolites in an Isolated Perfused Rat Lung

Laura A. Maertens
Pramod Upadhyaya
Stephen S. Hecht
Cheryl L. Zimmerman

Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Weaver-Densford Hall (L.A.M., C.L.Z.)

Masonic Cancer Center, University of Minnesota (P.U., S.S.H.)
Running Title: NNK metabolism in rat lung

Corresponding Author: Cheryl L. Zimmerman, College of Pharmacy, Department of Pharmaceutics, University of Minnesota, 308 Harvard St SE., 9-149B Weaver-Densford Hall, Minneapolis, MN 55455  E-mail: zimme005@umn.edu  Tel: (612)-624-4611  Fax: (612)-626-2125

# Text Pages: 36
# Tables: 3
# Figures: 5
# References: 32

Abstract: 249 words

Introduction: 641 words

Discussion: 1677 words

Abbreviations: NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNAL, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol; NNK-N-oxide, 4-(methylnitrosamino)-1-(3-pyridyl-N-oxide)-1-butanone; NNAL-N-oxide, 4-(methylnitrosamino)-1-(3-pyridyl-N-oxide)-1-butanol; keto alcohol, 4-oxo-4-(3-pyridyl)butanol; keto acid, 4-oxo-4-(3-pyridyl)butyric acid; diol, 4-hydroxy-4-(3-pyridyl)butanol; hydroxy acid, 4-hydroxy-4-(3-pyridyl)butyric acid; PEITC, phenethyl isothiocyanate; HEPES, N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid; ACN, Acetonitrile; HPLC, High Pressure Liquid Chromatography; LSC, Liquid Scintillation Counting; GC, Gas Chromatography; IPRL, Isolated Perfused Rat Lung; O⁶-POB-dGuo, O⁶-[4-(3-pyridyl)-

2
4-oxobut-1-yl]-2'-deoxyguanosine; \( O^2\text{-POB-dThd} \), \( O^2\text{-[4-(3-pyridyl)-4-oxobut-1-yl]thymidine} \); \( 7\text{-POB-Gua} \), 7-[4-(3-pyridyl)-4-oxobut-1-yl]guanine; \( O^6\text{-PHB-dGuo} \), \( O^6\text{-[4-(3-pyridyl)-4-hydroxybut-1-yl]-2'-deoxyguanosine} \); \( O^2\text{-PHB-dThd} \), \( O^2\text{-[4-(3-pyridyl)-4-hydroxybut-1-yl]thymidine} \); \( 7\text{-PHB-Gua} \), 7-[4-(3-pyridyl)-4-hydroxybut-1-yl]guanine; \( O^6\text{-methyl-Gua} \), \( O^6\text{-methylguanine} \).
ABSTRACT

4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone [NNK] is a lung-specific tobacco carcinogen. Metabolism is critical to its elimination given its lipophilic nature. While NNK can be metabolized through detoxification pathways that safely eliminate it from the body, it can also be bioactivated, resulting in the formation of potentially carcinogenic DNA adducts. The isolated perfused rat lung (IPRL) system was used to determine the effect of NNK perfusate concentration (0.1 µM and 1.2 µM) on the formation and distribution of metabolites, the level of individual DNA adducts, and total covalent binding in the lung. Co-administration of the chemopreventive agent, phenethyl isothiocyanate (PEITC, 20 µM), was also examined to determine its effect on NNK metabolism. NNK was readily metabolized in the IPRL system. In the 0.1 µM perfusions approximately 55% of metabolites formed were through detoxification pathways, while roughly 30% were the result of bioactivation pathways. An increase in NNK concentration increased the percent of unmetabolized NNK and decreased the apparent metabolic clearance in the lung, but the metabolite profiles remained similar between concentrations. The addition of PEITC reduced the formation of oxidative metabolites, and increased NNAL formation and the percent of unmetabolized NNK. PEITC also significantly decreased the formation of DNA adducts in the lung tissue. The level of $O^2$-POB-dThd and $O^6$-POB-dGuo decreased by 70 – 75%, and $O^6$-methyl-Gua and 7-POB-Gua decreased by 40 – 45 %. PHB-DNA adducts were not detected in any of the treatment groups. Thus, the IPRL system is useful in determining pulmonary metabolism and DNA adduct formation separate from other metabolizing organs.
INTRODUCTION

4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone [NNK] is a tobacco-specific carcinogen. It has been established as a strong carcinogen in rodents (Hecht, 1998), and has been classified as a human carcinogen by the International Agency for Research on Cancer [IARC] (2007). One of the most intriguing characteristics of NNK is its ability to selectively induce pulmonary tumors in rodents (Hecht, 1998). This lung specificity, along with biochemical and epidemiologic data, implicate NNK as a plausible contributor to the development of lung cancer in smokers (Hecht, 2003; 2007; Yuan et al., 2009).

The carcinogenic effects of NNK are primarily attributed to its metabolic activation. NNK is extensively metabolized in rodents and humans, which is illustrated by the low levels of NNK excreted unchanged in the urine (Hecht, 1998). An important metabolic pathway of NNK is carbonyl reduction to NNAL, a carcinogenic metabolite that undergoes subsequent metabolism through pathways parallel to those of NNK (Figure 1). Both NNK and NNAL are detoxified via N-oxidation to form their respective N-oxide metabolites, 4-(methyl nitrosamino)-1-(3-pyridyl-N-oxide)-1-butanone (NNK-N-oxide) or 4-(methyl nitrosamino)-1-(3-pyridyl-N-oxide)-1-butanol (NNAL-N-oxide). Likewise, both compounds undergo bioactivation through their α-hydroxylation pathways, resulting in the formation of DNA adducts. α-Methylene hydroxylation of NNK and NNAL results in the formation of the reactive intermediate methanediazohydroxide, which can form methyl DNA adducts. This pathway ultimately results in the formation of the metabolites 4-oxo-4-(3-pyridyl)butyric acid (keto acid) and 4-hydroxy-4-(3-pyridyl)butyric acid (hydroxy acid). When NNK undergoes α-methyl hydroxylation, the unstable intermediate 4-(3-pyridyl)-4-oxobutanediazohydroxide is
formed, which can react with water to yield the metabolite 4-oxo-4-(3-pyridyl)butanol (keto alcohol) or bind to DNA to form pyridyloxobutyl (POB)-DNA adducts. Similarly, the α-methyl hydroxylation of NNAL can produce pyridylhydroxybutyl (PHB)-DNA adducts or the metabolite 4-hydroxy-4-(3-pyridyl)butanol (diol). Previous in vivo studies in which NNK and NNAL were chronically administered in the drinking water of rats showed that the POB and PHB-DNA adducts that developed in the lung included \( O^6-[4-(3\text{-pyridyl})-4\text{-oxobut-1-yl}]-2\text{'-deoxyguanosine} \) (\( O^6\text{-POB-dGuo} \)), \( O^2-[4-(3\text{-pyridyl})-4\text{-oxobut-1-yl}]\text{thymidine} \) (\( O^2\text{-POB-dThd} \)), 7-[4-(3-pyridyl)-4-oxobut-1-yl]guanine (7-POB-Gua), \( O^6-[4-(3\text{-pyridyl})-4\text{-hydroxybut-1-yl}]-2\text{'-deoxyguanosine} \) (\( O^6\text{-PHB-dGuo} \)), \( O^2-[4-(3\text{-pyridyl})-4\text{-hydroxybut-1-yl}]\text{thymidine} \) (\( O^2\text{-PHB-dThd} \)), and 7-[4-(3-pyridyl)-4-hydroxybut-1-yl]guanine (7-PHB-Gua) (Lao et al., 2006; Lao et al., 2007; Upadhyaya et al., 2008). The formation of the methyl adduct \( O^6\text{-methylguanine} \) (\( O^6\text{-methyl-Gua} \)) after exposure to NNK was also observed (Upadhyaya et al., 2009), which is consistent with previous studies (Belinsky et al., 1986; Belinsky et al., 1991; Devereux et al., 1991; Hecht, 1998).

The lung tumorigenicity of NNK in rats is inhibited by phenethyl isothiocyanate [PEITC] (Morse et al., 1989; Hecht et al., 1996). PEITC is found as a conjugate in certain cruciferous vegetables, such as watercress. In vitro and in vivo data indicate that PEITC inhibits the oxidative metabolism of NNK resulting in a decrease in DNA adduct formation in the lung, thus inhibiting the carcinogenic effects of NNK (Morse et al., 1989; Staretz and Hecht, 1995; Hecht et al., 1996; Staretz et al., 1997a; Staretz et al., 1997b).
Since metabolic activation appears crucial to lung tumor formation, it is necessary to examine the pulmonary metabolism of NNK separately from other metabolizing organs, such as the liver. The isolated perfused rat lung system (IPRL) maintains the structural integrity of the lung, potentially providing a system more representative of localized in vivo metabolism than other in vitro systems. The purpose of this study was to better understand the carcinogenicity of NNK in the lung by examining the effects of PEITC and NNK concentration on perfusate and tissue metabolites, as well as DNA adduct formation in the IPRL system. The present lung perfusions expand on previous studies by quantitating metabolites in the tissue as well as in the perfusate, allowing for a better understanding of the distribution of metabolites between the perfusate and the tissue. Furthermore, the characterization of individual DNA adducts shows that metabolic bioactivation in lung leads directly to DNA damage, without the contribution of the liver. This is the first study to our knowledge to examine the formation of DNA adducts and the effect of PEITC on NNK metabolism in the lung using the IPRL system.
MATERIALS AND METHODS

Chemicals

Unlabeled NNK, racemic NNAL, NNK-N-oxide, NNAL-N-oxide, keto alcohol, keto acid, and diol were purchased from Toronto Research Chemicals (North York, Ontario). Hydroxy acid was synthesized as previously reported (McKennis et al., 1964). [5-^{3}H] NNK (21.7 Ci/mmol) was purchased from Moravek Biochemicals (Brea, CA). HPLC grade ACN and isopropanol were obtained from Fisher Scientific (Hampton, NH). Dextran 70 was acquired from Pharmacosmos (Holbaek, Denmark). The Puregene® DNA isolation kit was purchased from Qiagen (Germantown, MD). PEITC, bovine serum albumin (A7906-500G), and all other chemicals were acquired from Sigma-Aldrich (St. Louis, MO).

Animals

Male Fisher 344 rats were purchased from Charles River Laboratories (Portage, MI). They were housed two to three per cage containing corn cob bedding, and were maintained under standard conditions (20 ± 2 °C, 12 h light-dark cycle). Animals were given food (Teklad 2018, Harlan, Madison, WI) and water ad libitum. After arrival, they were allowed to acclimate in the housing facility for at least 1 week before use. The animal protocol for these experiments was approved by the University of Minnesota Institutional Animal Care and Use Committee (IACUC).
Isolated Lung Perfusion

The general principles of the isolated lung perfusion procedure used were adopted from the laboratory of Dr. Douglas Wangensteen (University of Minnesota) and have been previously described (Wangensteen et al., 1986; Wangensteen et al., 1996). To remove the lungs from the chest cavity, rats were anesthetized with a 60 mg/kg intraperitoneal dose of pentobarbital sodium (Ovation Pharmaceuticals, Deerfield, IL). A tracheotomy was performed and a 0.75 - 1 in piece of PE 240 tubing (Becton Dickinson, Sparks, MD) was inserted into the trachea and tied securely into place with suture (Deknatel, Mansfield, MA). Next, an incision was made into the abdomen and the chest cavity was opened by cutting up the midline of the rib cage. The chest cavity was held open with a retractor, and 100 units of heparin sodium (APP Pharmaceuticals, Schaumburg, IL) were slowly injected into the right heart immediately below the pulmonary artery. A small incision was then made at the site of the heparin injection and a polyethylene cannula (PE 190) connected to the perfusate supply was inserted into the pulmonary artery and tied into place. The heart was cut thoroughly to allow for unrestricted flow of perfusate out of the lung. The lungs were then excised from the chest cavity and suspended by the trachea from a ring stand, where they were rinsed of blood with perfusate. The lungs were inflated and deflated two to three times to help facilitate the removal of the blood from the vessels, following which they were inflated at a constant pressure of 4 cm H₂O. The flow rate was set to 8 mL/min, and once the lungs were adequately rinsed, as determined by visual inspection, they were placed in the jacketed beaker that served as the reservoir.
The lungs were perfused in a 50 mL recirculating system with a Ringers solution (pH 7.4) that was comprised of 2.68 mM KCl, 1.25 mM MgSO\textsubscript{4}·7H\textsubscript{2}O, 1.82 mM CaCl\textsubscript{2}, 5.55 mM D-glucose, 137 mM NaCl, 12 mM HEPES, 1% dextran 70, and 0.5% albumin. The perfusate was oxygenated with 95% O\textsubscript{2} and 5% CO\textsubscript{2}, and the system was maintained at 37 °C. The pressure, temperature, and pH were monitored with transducers throughout the perfusion. A lung was discarded if excessive swelling and water retention were observed throughout the course of the perfusion.

**Metabolism Studies**

The metabolism of NNK in the lung was examined using two initial concentrations of [5-\textsuperscript{3}H] NNK with and without PEITC. Three animals were used for each of four treatments: 1) 0.1 μM NNK; 2) 0.1 μM NNK + 20 μM PEITC; 3) 1.2 μM NNK; and 4) 1.2 μM NNK + 20 μM PEITC. Once the lungs were rinsed of blood and a recirculating perfusion was established, a bolus dose of each of the appropriate compounds was injected into the perfusate reservoir. Perfusate samples of 250 μL were taken from the reservoir at 0, 1, 5, 10, 20, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165 and 180 min post dose. After the final sample was collected, the lungs were perfused with 50 mL of blank perfusate. The tissue was then minced, weighed, flash-frozen in liquid nitrogen, and stored at -80 °C until further analysis.

**DNA Adduct Studies**

The perfusions for studying DNA adducts were carried out in the same manner as those conducted for metabolism, except that unlabelled NNK was used and perfusate samples were not collected. After the 180 min perfusion the lungs were perfused with 50 mL of blank perfusate; the tissue was then minced, weighed, flash-frozen in liquid
nitrogen, and stored at -80 °C until analysis for individual DNA adduct formation was performed.

**Perfusate Analysis**

The amount of total radioactivity in each perfusate sample was determined by analyzing a 50 μL aliquot by LSC. The remaining 200 μL of each sample was used to quantitate metabolite formation. Protein was precipitated from the perfusate samples by adding 500 μL of ACN, vortexing, then centrifuging at 13,000 x g (235B, Fisher Scientific) for three min. The supernatant was then concentrated to dryness with a stream of nitrogen while heating in a 37 ºC water bath. The samples were reconstituted with 220 μL of 20 mM NaHPO₄ buffer containing 1 mM EDTA, and centrifuged at 13,000 x g for 1 min. The metabolites were analyzed by injecting 100 μL of the final supernatant onto HPLC with UV and radioflow detectors.

**Tissue Analysis: Metabolites and Total Covalent Binding**

Tissue samples from the metabolism perfusions were used to quantitate the metabolites and to estimate the total covalent binding in the tissue. The lung samples were homogenized with a PowerGen 125 homogenizer (Fisher Scientific). A small aliquot of homogenate was solubilized with 6 mL of 1M NaOH and analyzed by LSC to estimate the total radioactivity in the tissue. The remaining homogenate was used to quantitate the metabolites and covalent binding in the lung.
DMD #31492

Metabolites

To the remaining homogenized lung tissue, 6 mL of 0.1M HCl was added and the tissue was further homogenized. The sample was then centrifuged at 2950 x g (Sorvall Legend RT, Fisher Scientific) for 30 min. The resulting tissue pellet was used for total covalent binding analysis. The resulting cloudy supernatant was used to determine tissue metabolites and was transferred to a clean test tube and neutralized. To buffer the solution, 1 mL of 0.1 M NaPO₄ was added to the supernatant before neutralizing with 1M NaOH. The neutralized supernatant was then centrifuged at 1228 x g (IEC Medispin) for 20 min. The resulting clear supernatant was transferred and concentrated to dryness in a 37 °C water bath with a stream of nitrogen. Once dried, the sample was reconstituted with 400 μL of distilled H₂O. Tissue metabolites were determined by injecting 100 μL of the reconstituted sample onto HPLC with UV and radioflow detectors.

Total Covalent Binding

The tissue pellet that remained after the initial metabolite extraction was used to estimate the total covalent binding in the lung tissue. The pellet was homogenized with 6 mL aliquots of 0.1M HCl and then centrifuged at 1228 x g for 15 min until the counts in the wash solution were not more than twice the level of background, approximately nine washes. The tissue pellet was then solubilized with 10 mL of 1M NaOH, and analyzed by LSC. The protein concentration of the solubilized tissue pellet was determined using the BCA Protein Assay Kit (Fisher Scientific) with an albumin standard.
HPLC Analysis

HPLC analysis was performed on a system that consisted of a Waters 600 system controller, two Waters 501 pumps, a Waters 440 absorbance detector (254 nm) (Waters Corp., Milford, CA), a Hewlett Packard 1100 series autosampler (Santa Clara, CA), and a β-ram radioflow detector (IN/US Systems, Tampa, FL). A Luna C\textsubscript{18}(2) reversed-phase column (250 x 4.6 mm, 5 \textmu m; Phenomenex, Torrance, CA) was used for the separation. The metabolites were eluted using a linear gradient from 92 \% A (20 mM NaHPO\textsubscript{4} and 1 mM EDTA, pH 6.0) to 80\% A over 30 min, and then to 50\% A in 5 min; B was acetonitrile (Jalas et al., 2003). The flow rate was 0.5 mL/min, which was mixed with 1.5 mL/min of Monoflow\textsuperscript{®} (National Diagnostics, Atlanta, GA).

DNA Isolation

DNA was isolated using a slightly modified version of the Gentra Puregene\textsuperscript{®} Tissue Kit protocol. A single lung was weighed and divided into approximately two 500 mg aliquots. The samples were kept frozen on dry ice and minced with a razor blade. The aliquots were transferred to a 15 mL glass homogenizer containing 5 mL of Cell Lysis Solution and homogenized on ice. The homogenate was transferred to a 50 mL centrifuge tube into which the remaining 13 mL of Cell Lysis Solution was added. Then 75 \mu L of Puregene Proteinase K were added and the tubes were inverted 25 times before being placed in an orbital shaker (Maxq 4450, Fisher Scientific) and shaken at 80 rpm overnight at 55°C. Once the tissue was completely lysed, 90 \mu L of RNase A Solution were added. The tubes were inverted 25 times and then replaced in the orbital shaker for 60 min at 80 rpm and 37°C. The solution was then put on ice for 3-5 min. Six mL of Protein
Precipitation Solution were added and the samples were vortexed on high for approximately 20 sec. The samples were then centrifuged at 2000 x g (Sorvall Legend RT) for 10 min. The resulting supernatant was carefully poured into a clean 50 mL tube containing 18 mL of ice cold 100% isopropanol. The tube was slowly inverted 50 times resulting in the formation of a clump of DNA strands. The DNA was rinsed three times with 6 mL aliquots of 70% cold EtOH, and then three more times with 6 mL aliquots of 100% cold EtOH. The DNA was then dried with a gentle stream of nitrogen. Samples were stored at -4 ºC until further analysis.

Quantitation of DNA adducts

DNA adduct formation was analyzed using the LC/ESI-MS/MS-SRM method previously described for POB or PHB DNA adducts (Lao et al., 2006; Lao et al., 2007; Upadhyaya et al., 2008). Briefly, deuterated POB or PHB internal standards were added to 0.5 - 2 mg of isolated DNA and neutral thermal hydrolysis was carried out at 100 ºC for 30 min. Then, enzymatic hydrolysis was carried out with micrococcal nuclease, phosphodiesterase II (Worthington Biochemical Corp, Lake Wood, NJ), and alkaline phosphatase (Roche Molecular Biochemicals, Indianapolis, IN). The resulting hydrolysate was then purified by solid-phase extraction (Strata-X cartridge, Phenomenex, Torrance, CA)), and injected into a Finnigan TSQ Quantum Discovery Max triple quadrupole mass spectrometer (Thermo Electron, San Jose, CA). The limit of detection for the POB and PHB adducts were: 7-POB-Gua (3 fmol/mg DNA), O6-POB-dGuo (1 fmol/mg DNA), O2-POB-dThd (100 amol/mg DNA), 7-PHB-Gua (18 fmol/mg DNA), O6-PHB-dGuo (1.5 fmol/mg DNA), and O2-PHB-dThd (1.5 fmol/mg DNA).
For $O^6$-methyl-Gua analysis, 0.05 - 1 mg of each DNA sample plus $[CD_3]O^6$-methyl-Gua internal standard was dissolved in 1 mL of HCl (0.1N) and heated at 80 °C for 30 min, cooled, and neutralized with 1N NaOH to pH 7.0. The resulting solution was applied to a solid-phase extraction cartridge (Strata-X) and analyzed by capillary LC/ESI-MS/MS-SRM as described previously (Upadhyaya et al., 2009). The limit of detection for $O^6$-methyl-Gua was 3 fmol/mg DNA.

**Pharmacokinetic Analysis**

The apparent pharmacokinetic parameters for the metabolism of NNK in the lung were estimated by non-compartmental analysis of the NNK concentration-time data in the perfusate using WinNonlin® version 5.2 (Pharsight, Mountain View, CA). The area under the curve from 0 to 180 min ($AUC_{180}^0$) was calculated by WinNonlin via the linear trapezoidal rule. The $AUC_{180}^\infty$ was extrapolated using the concentration of NNK in the perfusate at 180 min ($C_{\text{last}}$) and the estimated elimination rate constant, $\lambda_z$. The concentration-time data from 45 min to 180 min were used to estimate $\lambda_z$, using uniform weighting. The combined value of AUCs yielded the $AUC_{0}^{\infty}$, which was used to calculate the apparent clearance ($CL_{\text{app}}$). The apparent extraction ratio ($ER_{\text{app}}$) was calculated by dividing $CL_{\text{app}}$ by the perfusate flow rate (8 ml/min).

**Statistical Analysis**

Statistical analysis of the data was carried out using SigmaStat version 3.1 (Aspire Software International, Ashburn, VA). Unpaired t-tests were used to compare tissue metabolites, perfusate metabolite AUCs, total covalent binding, and individual DNA
adduct levels between the PEITC and non-PEITC groups at the two doses. A 2-way ANOVA was used to compare the apparent pharmacokinetic parameters between the PEITC and non-PEITC groups at each dose, and to compare the parameters between the two doses of NNK. The Holm-Sidak method was used for pairwise multiple comparisons. A p-value of < 0.05 was considered significant for all tests.
RESULTS

0.1 μM NNK

The perfusate concentration-time profiles of NNK and its metabolites in the 0.1 μM NNK perfusions are shown in Figure 2 (A, C, E). Figure 2A shows the concentration profile of NNK. Less than 5% of the final metabolites were attributed to unmetabolized NNK after the 180 min perfusion. The NNK concentration-time data were used to estimate the apparent pharmacokinetic parameters (Table 1). The apparent metabolic clearance of the lung (CL_app) was 1.07 ± 0.09 mL/min, the apparent extraction ratio (ER_app) was 0.13 ± 0.01, and the apparent half-life (t1/2_app) was 34 ± 5 min.

NNK-N-oxide was the major metabolite in the perfusate with a concentration of 33.8 ± 0.8 pmol/mL, which accounted for approximately 49% of the total metabolites in the perfusate. The final concentration of keto alcohol (14.0 ± 0.4 pmol/mL) in the perfusate was greater than that of keto acid (8.0 ± 1.2 pmol/mL). NNAL (5.3 ± 0.4 pmol/mL) and its subsequent metabolites were formed to a lesser extent than the NNK metabolites. However, the subsequent metabolism of NNAL was analogous to that of NNK. NNAL-N-oxide (3.6 ± 0.4 pmol/mL) was the major NNAL metabolite, followed by diol (2.0 ± 0.2 pmol/mL). Hydroxy acid was not detected in the perfusate.

The metabolite profile in the tissue differed from that in the perfusate. In the tissue, hydroxy acid (0.77 ± 0.37 pmol/mg protein) and NNAL-N-oxide (0.32 ± 0.06 pmol/mg protein) were the major metabolites, accounting for approximately 42% and 17% of the total tissue metabolites (Figure 3). The only DNA adduct that was detectable in the 0.1 μM NNK perfusions was O^2-POB-dThd (Table 2).
0.1 μM NNK + 20 μM PEITC

Figure 2 (B, D, F) illustrates the concentration-time data for NNK and its metabolites in the perfusate of the 0.1 μM NNK + PEITC perfusions. Compared to the 0.1 μM NNK perfusions, the metabolism of NNK was reduced in the presence of PEITC. Unmetabolized NNK (26.4 ± 3.0 pmol/mL) accounted for approximately 30-40% of the metabolites at the end of the perfusion with PEITC, compared to less than 5% when NNK was perfused alone. The observed decrease in NNK metabolism corresponded to changes in its apparent pharmacokinetic parameters (Table 1). There was a significant decrease in ER_app and CL_app from 0.13 ± 0.01 to 0.05 ± 0.01, and 1.07 ± 0.09 mL/min to 0.39 ± 0.03 mL/min, respectively. Meanwhile, the t1/2_app increased significantly from 34 ± 5 min to 108 ± 8 min in the presence of PEITC.

The formation of all metabolites, except NNAL, was decreased with the addition of PEITC. NNK-N-oxide (17.0 ± 2.1 pmol/mL) remained the major metabolite in the perfusate, but only accounted for approximately 24% of the total perfusate metabolites, instead of the 49% that was observed when NNK was administered alone. Keto alcohol (9.5 ± 1.0 pmol/mL) still formed to a greater extent than keto acid (4.2 ± 0.2 pmol/mL), but the overall formation of both bioactivation metabolites was decreased. The concentration of NNAL (11.6 ± 1.1 pmol/mL) increased, while the formation of its subsequent metabolites, NNAL-N-oxide (2.0 ± 0.3 pmol/mL) and diol (1.2 ± 0.2 pmol/mL) decreased along with the other oxidative metabolites. To determine the effect of PEITC on metabolite formation, the AUC from time 0 to 180 min was calculated for each perfusate metabolite (Table 3). There was a significant decrease (p-value < 0.05) in
AUC for all oxidative metabolites and a significant increase in AUC for NNAL and NNK when PEITC was co-administered with NNK.

While the concentration of metabolites in the perfusate changed significantly with the addition of PEITC, overall there was not a significant change in metabolite concentrations in the tissue. Hydroxy acid (0.70 ± 0.12 pmol/mg protein) remained the major tissue metabolite, followed by NNAL-N-oxide (0.35 ± 0.05 pmol/mg protein). While tissue metabolite concentrations seemed unaffected, covalent binding in the tissue decreased significantly with the presence of PEITC. The level of $O^2$-POB-dThd was significantly decreased from 36.0 ± 2.9 fmol/mg DNA when NNK was perfused alone, to 9.9 ± 2.0 fmol/mg DNA when PEITC was co-administered (Table 2). The total covalent binding also decreased significantly from 0.25 ± 0.01 pmol/mg protein to 0.17 ± 0.02 pmol/mg protein.

1.2 μM NNK

The perfusate concentration-time profiles of NNK and its metabolites in the 1.2 μM NNK perfusions are depicted in Figure 4 (A, C, E). Unmetabolized NNK (138 ± 45 pmol/mL) constituted approximately 16% of the compounds in the perfusate at the end of the perfusion, which was greater than the 5% in the 0.1 μM NNK perfusions. The major perfusate metabolites were NNK-N-oxide (338 ± 64 pmol/mL) and keto alcohol (167 ± 29 pmol/mL). Overall, the metabolic profile in the perfusate was similar in the 1.2 μM and 0.1 μM NNK treatments. However, the higher dose of NNK appeared to have an inhibitory effect on the overall metabolism, resulting in a CL_{app} of 0.66 ± 0.09 mL/min, an ER_{app} of 0.08 ± 0.01, and a t_{1/2,app} of 64 ± 16 min (Table 1).
The major tissue metabolites were hydroxy acid (6.4 ± 1.9 pmol/mg protein) and NNAL-N-oxide (4.2 ± 1.2 pmol/mg protein), which accounted for approximately 32% and 21% of the total tissue metabolites (Figure 5). With the higher dose of NNK, more individual DNA adducts were detected in the tissue (Table 2). $O^2$-POB-dThd (362 ± 11 fmol/mg DNA) and $O^6$-methyl-Gua (284 ± 14 fmol/mg DNA) were formed to a greater extent than $O^6$-POB-dGuo (43.7 ± 2.4 fmol/mg DNA) and 7-POB-Gua (32.1 ± 3.2 fmol/mg DNA) in the tissue. None of the individual PHB-DNA adducts were present at detectable levels in the lung.

**1.2 μM NNK + 20 μM PEITC**

The presence of PEITC inhibited the metabolism of NNK (Figure 4B). Approximately 48% of the final perfusate compounds was attributable to NNK (345 ± 34 pmol/mL), which was significantly greater than the 16% associated with NNK (138 ± 45 pmol/mL) when 1.2 μM NNK was dosed alone. The formation of all metabolites, except NNAL, was inhibited by PEITC (Figure 4D & F). The major perfusate metabolites were NNAL and NNK-N-oxide, which had comparable concentrations. The concentration of NNAL increased from 85.4 ± 8.1 pmol/mL when NNK was perfused alone, to 124 ± 12 pmol/mL with the co-administration of PEITC. Meanwhile, the concentration of NNK-N-oxide decreased from 337 ± 64 pmol/mL to 120 ± 11 pmol/mL. The concentration of all other oxidative metabolites decreased as well. The presence of PEITC was associated with a significant decrease in AUC from 0 to 180 min for all oxidative metabolites and a
significant increase in the AUC of NNK (Table 3). A significant change in NNAL AUC was not observed. The addition of PEITC resulted in a decrease in CL_{app} from 0.66 ± 0.09 mL/min to 0.36 ± 0.03 mL/min. A decrease in ER_{app} from 0.08 ± 0.01 to 0.04 ± 0.00 was also observed, while t_{1/2,app} increased from 64 ± 16 min to 149 ± 11 min (Table 1).

In the tissue, hydroxy acid (7.9 ± 1.9 pmol/mg protein) and NNK (2.5 ± 0.5 pmol/mg protein) had the highest concentrations. Overall there did not appear to be a consistent change in the tissue concentrations of metabolites with the addition of PEITC (Figure 5). The reduction in NNK metabolism led to a decrease in covalent binding in the tissue. The estimated total covalent binding significantly decreased from 2.28 ± 0.02 pmol/mg protein to 1.38 ± 0.29 pmol/mg protein. The formation of individual DNA adducts also decreased significantly with the administration of PEITC (Table 2). The major DNA adduct in the tissue was O^6-methyl-Gua (163 ± 3 fmol/mg DNA), followed by O^2-POB-dThd (89.2 ± 2.2 fmol/mg DNA), 7-POB-Gua (18.0 ± 10.0 fmol/mg DNA), and O^6-POB-dGuo (11.4 ± 2.1 fmol/mg DNA).
DISCUSSION

Comparison to previous IPRL study

This study examined the effects of NNK concentration and the co-administration of PEITC on metabolism, metabolite distribution, and DNA adduct formation in the perfused rat lung. The final metabolite composition in the perfusate of the 0.1 µM NNK perfusions was similar to the 0.035 µM NNK perfusion previously reported, despite a number of differences in the experimental designs (Schrader et al., 1998). Both studies found that a majority of the metabolites formed were from detoxification pathways (55%), while bioactivation pathways account for approximately 30% of metabolism. The extent of formation of most metabolites was in agreement between the two studies, with the exception of minor differences in the formation of diol and keto alcohol.

While the extent of metabolite formation was comparable between the two studies, the estimated apparent clearance (CL_{app}) was lower in the present study (1.07 ± 0.9 mL/min) than in the previous study (2.1 ± 0.5 mL/min). The difference in CL_{app} may be attributable to the concentration difference of NNK between the two experiments, since clearance was shown to decrease with increased concentration in the present study. Since the CL_{app} is much lower than perfusate flow, NNK is a low extraction ratio compound with respect to the lung.

The present study examined the metabolites in the lung tissue. Less than 4% of the radioactivity was recovered in the lung, and the metabolite profile of the tissue was different than that of the perfusate. Hydroxy acid was not detected in the perfusate in any of the treatment groups, but it was the major metabolite in the tissue for all groups. This may be due to diffusional barriers within the lung. Hydroxy acid is the most hydrophilic
of the metabolites and thus may not transverse the membranes as easily as the other more lipophilic metabolites, resulting in its accumulation in the lung tissue. In both studies the estimated apparent volumes of distribution were approximately equal to the volume of the reservoir, indicating that the partitioning of NNK and its metabolites into the lung tissue was not extensive.

It is important to note that the pharmacokinetic parameters that are reported here are apparent values. The equations that were used to estimate these parameters were derived based on the assumption that no reversible metabolism takes place in the system. Reconversion of NNAL to NNK is possible (Upadhyaya et al., 2000), but the extent of the reconversion in this system is unknown. If the reoxidation of NNAL to NNK is minor in the lung, then the estimates provided here should be fairly accurate. However, if the reconversion of NNAL to NNK is extensive, then the clearance of NNK from the lung reported here would be underestimated. Studies investigating the reconversion of NNAL to NNK in the IPRL are currently in progress.

**Effects of NNK Concentration**

The dose dependent carcinogenicity of NNK has been investigated *in vivo* (Hecht et al., 1980; Hoffmann et al., 1984; Belinsky et al., 1990). In the study performed by Belinsky *et al.*, doses of NNK ranging from 30 nmol (0.03 mg/kg) to 48,000 nmol (50 mg/kg) were administered to F344 rats subcutaneously three times a week for 20 weeks. The lowest dose administered (30 nmol/dose) induced lung tumors, but the formation was not significantly different from the control rats. The lowest dose that resulted in a significant formation of lung tumors was approximately 90 nmol/dose. The high dose
used in the present study was the average of those two doses, 60 nmol, which achieved an initial perfusate concentration of 1.2 µM. The 0.1 µM perfusate concentration was the result of a 5 nmol NNK dose, which was the lowest achievable dose in initial perfusions when 50 µCi of [5- 3H] NNK was administered. Given that both high and low dosing schemes had been used to test the tumorigenicity of NNK, it was of interest to determine the effects of dose on the metabolism and DNA adduct formation in the lung.

NNK at a concentration of 0.1 µM was effectively metabolized in the lung. When the NNK concentration was increased twelve-fold to 1.2 µM the efficiency of the lung metabolism appeared to decrease, as is evident by the decrease in apparent clearance. The increase in dose did result in a moderate decrease in the extent of formation of NNK-N-oxide, a modest increase in NNAL, and an increase in unmetabolized NNK at the end of the 180 min perfusion. NNK-N-oxide remained the major metabolite at 40% of the perfusate metabolites, as opposed to 50% at the lower dose. At the end of the 1.2 µM perfusion there was more unmetabolized NNK in the perfusate than after the 0.1 µM perfusion. These results are supported by in vitro metabolism studies of NNK in alveolar type II cells. Those studies showed that higher doses of NNK reduce the formation of NNK-N-oxide and the other oxidative metabolites, while increasing the formation of NNAL and the level of unmetabolized NNK (Schrader et al., 2000). Another in vitro study by Richter et al., showed that NNK concentration did not greatly affect metabolite formation in the lung tissue of rats (Richter et al., 2009). However, they did observe that an increased NNK concentration was accompanied by an increase in NNAL at the “expense” of NNK-N-oxide. It is possible that higher doses of NNK saturated certain critical cytochrome P450 metabolic pathways, resulting in shunting through the NNAL
pathway. However, the enzymes responsible for NNAL formation were apparently not efficient enough to compensate for the decrease in P450 activity, so overall less NNK was metabolized. The saturation of metabolism with increased NNK is also supported by the work of Devereux et al., which showed a decrease in the efficiency of $O^6$-methyl-Gua formation with an increase in NNK (Devereux et al., 1988).

$O^2$-POB-dThd was the only DNA adduct detected in the tissue at the low concentration of NNK, and was the major POB-DNA adduct detected in the lung of rats that were chronically treated with NNK in the drinking water (Lao et al., 2006; Lao et al., 2007). No other DNA adducts were detected in the lung tissue of the 0.1 $\mu$M perfusions. The metabolite profiles indicate that the intermediates for methyl and PHB-DNA adducts were formed, but those adducts were not detected. In the 1.2 $\mu$M perfusions all three POB-DNA adducts and $O^6$-methyl-Gua were detected, but none of the PHB-DNA adducts were observed in the lung tissue. $O^2$-POB-dThd remained the major POB-DNA adduct. There was slightly more $O^6$-POB-dGuo than 7-POB-Gua in the lung, which was in contrast to the in vivo results that showed 7-POB-Gua at a significantly greater level than $O^6$-POB-dGuo throughout the entire 20 week bioassay (Lao et al., 2007). It is possible that there is an efficient DNA repair mechanism for $O^6$-POB-dGuo that reduces its level in the rat lung in vivo, but would not be present in the lung perfusion system. The formation of DNA adducts in the IPRL system further supports the idea that bioactivation in the lung, and not the liver, is responsible for the development of pulmonary tumors (Weng et al., 2007).
Effects of PEITC

PEITC inhibits the formation of NNK-induced lung tumors in rats (Morse et al., 1989; Hecht et al., 1996). The chemopreventive nature of PEITC has been attributed to its ability to inhibit P450 metabolism, resulting in a decrease in the bioactivation of NNK, thus decreasing the formation of potentially carcinogenic DNA adducts (Smith et al., 1990; Guo et al., 1991; Guo et al., 1992; von Weymarn et al., 2006). The addition of PEITC to the perfusion system resulted in a significant decrease in the formation of all perfusate oxidative metabolites and an increase in NNAL formation, regardless of the NNK dose. The carbonyl reduction of NNK to NNAL is considered to be primarily catalyzed through non-P450 pathways, for example by 11-β-hydroxysteroid, aldo-keto reductase (AKR), and carbonyl reductase (CR) (Atalla and Maser, 1999; Breyer-Pfaff et al., 2004), which could explain the apparent lack of inhibition of NNAL formation. In fact, the increase in NNAL formation could be due to shunting through the carbonyl reduction pathway as a result of the decrease in P450 oxidative metabolism. Previous in vitro studies also showed a decrease in the formation of oxidative metabolites with the treatment of PEITC (Smith et al., 1990; Guo et al., 1992; Staretz and Hecht, 1995; Staretz et al., 1997b). While the in vitro studies did not show a significant increase in NNAL formation, in vivo studies showed a significant increase in NNAL and NNAL-glucuronide in the urine of rats that were co-administered PEITC with NNK, as well as a significant decrease in hemoglobin adducts resulting from α-hydroxylation (Hecht et al., 1996).

The decrease in oxidative metabolism consequently led to a decrease in DNA adduct formation and total covalent binding in the tissue due to α-hydroxylation. The
addition of PEITC inhibited the formation of $O^2$-POB-dThd and $O^6$-POB-dGuo by 70 – 75%, and decreased the formation of $O^6$-methyl-Gua and 7-POB-Gua by 40 – 45 %. These results are consistent with previous in vivo and in vitro studies that showed a decrease in DNA adduct formation with the addition of PEITC (Morse et al., 1989; Guo et al., 1991; Staretz et al., 1997a).

In summary, the current study shows that increased NNK concentration results in a significant decrease in the apparent pulmonary clearance, with only minor shifts in the metabolite profiles. The detection of DNA adducts indicate that metabolic activation in the lung leads to DNA damage, and that bioactivation via the liver is not required. PEITC inhibits the formation of oxidative metabolites, which subsequently results in a decrease in DNA adduct formation. This study is the first to assess the pulmonary metabolism of NNK in the IPRL system that examined the time course of metabolite formation in the perfusate, quantitated the metabolites in the tissue, and measured the formation of individual DNA adducts. It is also the first study to examine the effect of PEITC on the pulmonary metabolism of NNK in the IPRL system. The results show the utility of the IPRL system in examining metabolism and DNA adduct formation in the lung.
ACKNOWLEDGEMENTS

A special thanks is due to Dr. Douglas Wangensteen, Dr. Peter Byron, and Dr. Hashiro Sakagami for demonstrating the isolated lung perfusion surgery and setup. The authors would also like to acknowledge Steve Carmella for his assistance with the technical aspects of this work.
REFERENCES


Upadhyaya P, Lindgren BR and Hecht SS (2009) Comparative levels of O6-methylguanine, pyridyloxobutyl-, and pyridylhydroxybutyl-DNA adducts in lung...
and liver of rats treated chronically with the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. *Drug Metab Dispos* **37**:1147-1151.


FOOTNOTES

This work was supported by the Public Health Service [Grants NCI CA-81301 to SSH]; and University of Minnesota Fellowships [3M Science and Technology Fellowship, Ted Rowell Graduate Fellowship, and Edward Rippie Fellowship to LAM].

Reprint requests can be directed to Cheryl L. Zimmerman, College of Pharmacy, Department of Pharmaceutics, University of Minnesota, 308 Harvard St SE., 9-149B Weaver-Densford Hall, Minneapolis, MN 55455 E-mail: zimme005@umn.edu
FIGURE LEGENDS

**Figure 1:** A simplified metabolic scheme of NNK and NNAL. (*) represents the location of the tritium label. A more detailed metabolic scheme has been previously published (Hecht, 1998).

**Figure 2:** Concentration (pmol/mL) ± SD vs time (min) profiles of NNK and metabolites in the perfusate of 0.1 µM NNK (A, C, E) and 0.1 µM NNK + PEITC (B, D, F), (n=3). Symbol designations are as follows: NNK, ●; NNK-N-oxide, ○; NNAL, ■; NNAL-N-oxide, □; keto alchol, ▲; keto acid, <; diol, ▲. The profile of NNAL is replotted in figures E and F for comparison purposes. Where error bars are not apparent, they are smaller than the symbol.

**Figure 3:** Concentration of metabolites (pmol/mg tissue) ± SD in the tissue after 180 min perfusion, (n=3). Open bars represent 0.1 µM NNK and shaded bars 0.1 µM NNK + PEITC. *p*-value < 0.05.

**Figure 4:** Concentration (pmol/mL) ± SD vs time (min) profiles of NNK and metabolites in the perfusate of 1.2 µM NNK (A, C, E) and 1.2 µM NNK + PEITC (B, D, F), (n=3). Symbol designations are as follows: NNK, ●; NNK-N-oxide, ○; NNAL, ■; NNAL-N-oxide, □; keto alchol, ▲; keto acid, <; diol, ▲. The profile of NNAL is replotted in figures E and F for comparison purposes. Where error bars are not apparent, they are smaller than the symbol.
Figure 5: Concentration of metabolites (pmol/mg tissue) ± SD in the tissue after 180 min perfusion, (n=3). Open bars represent 1.2 µM NNK and shaded bars 1.2 µM NNK + PEITC. *p-value < 0.05.
Table 1: The apparent pharmacokinetic parameters (mean ± SD, n=3) for the metabolism of NNK in the lung.

<table>
<thead>
<tr>
<th></th>
<th>0.1 µM NNK</th>
<th>0.1 µM + PEITC</th>
<th>1.2 µM NNK</th>
<th>1.2 µM + PEITC</th>
</tr>
</thead>
<tbody>
<tr>
<td>( t_{1/2,\text{app}} ) [min]</td>
<td>34 ± 5</td>
<td>108 ± 8(^a)</td>
<td>64 ± 16(^a)</td>
<td>149 ± 11(^b)</td>
</tr>
<tr>
<td>( V_z ) [mL]</td>
<td>51 ± 3</td>
<td>60 ± 1</td>
<td>61 ± 11</td>
<td>76 ± 3(^b)</td>
</tr>
<tr>
<td>( \text{CL}_{\text{app}} ) [mL/min]</td>
<td>1.07 ± 0.09</td>
<td>0.39 ± 0.03(^a)</td>
<td>0.66 ± 0.09(^a)</td>
<td>0.36 ± 0.03(^b)</td>
</tr>
<tr>
<td>( \text{ER}_{\text{app}} )</td>
<td>0.13 ± 0.01</td>
<td>0.05 ± 0.01(^a)</td>
<td>0.08 ± 0.01(^a)</td>
<td>0.04 ± 0.00(^b)</td>
</tr>
</tbody>
</table>

\(^a\) \( p\)-value < 0.05, when compared to 0.1 µM NNK

\(^b\) \( p\)-value < 0.05, when compared to 1.2 µM NNK

A 2-way ANOVA with Holm-Sidak was used for determining significant differences.
Table 2: The levels of individual DNA adducts (fmol/mg DNA) (mean ± SD, n=3) in the lung tissue after a 180 min perfusion. The initial concentrations of NNK in the perfusate were 0.1 µM and 1.2 µM.

<table>
<thead>
<tr>
<th>DNA Adducts</th>
<th>0.1 µM</th>
<th>1.2 µM</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>NNK</td>
<td>NNK + PEITC</td>
</tr>
<tr>
<td>$O^2$-POB-dThd</td>
<td>36.0 ± 2.9</td>
<td>9.9 ± 2.0$^a$</td>
</tr>
<tr>
<td>$O^6$-POB-dGuo</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>7-POB-Gua</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>$O^6$-methyl-Gua</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

PHB-DNA adducts were not detected in any of the lung tissue samples.

$^a$ p-value < 0.05
Table 3: The mean $AUC_0^{180}$ (pmol·min/mL) ± SD of perfusate metabolites (n=3).

<table>
<thead>
<tr>
<th></th>
<th>Keto Acid</th>
<th>NNAL-N-oxide</th>
<th>Diol</th>
<th>NNK-N-oxide</th>
<th>Keto Alcohol</th>
<th>NNAL</th>
<th>NNK</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.1 μM</td>
<td>700 ± 120</td>
<td>270 ± 40</td>
<td>150 ± 20</td>
<td>4050 ± 200</td>
<td>1960 ± 90</td>
<td>720 ± 50</td>
<td>4550 ± 320</td>
</tr>
<tr>
<td>0.1 μM + PEITC</td>
<td>370 ± 10$^a$</td>
<td>130 ± 20$^a$</td>
<td>70 ± 10$^a$</td>
<td>1550 ± 170$^a$</td>
<td>950 ± 80$^a$</td>
<td>1260 ± 80$^a$</td>
<td>8970 ± 350$^a$</td>
</tr>
<tr>
<td>1.2 μM</td>
<td>6060 ± 840</td>
<td>2490 ± 750</td>
<td>1380 ± 410</td>
<td>36700 ± 7400</td>
<td>19400 ± 3500</td>
<td>10700 ± 1300</td>
<td>78000 ± 7100</td>
</tr>
<tr>
<td>1.2 μM + PEITC</td>
<td>3400 ± 240$^a$</td>
<td>660 ± 320$^a$</td>
<td>450 ± 220$^a$</td>
<td>11000 ± 1800$^a$</td>
<td>7700 ± 1500$^a$</td>
<td>12900 ± 1100</td>
<td>96700 ± 5000$^a$</td>
</tr>
</tbody>
</table>

$^a$p-value < 0.05, compared to the same concentration without PEITC.
Figure 1
Figure 5

Metabolite Concentration [pmol/mg protein]

Hydroxy Acid  
Keto Acid  
NNAL-N-oxide  
Diol  
NNK-N-oxide  
Keto Alcohol  
NNAL  
NNK